IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments
15 Giugno 2023 - 12:00PM
IMAGIO consortium receives Innovative Health Initiative EUR 24
million grant to improve cancer treatments
June 15, 2023
- The Innovative Health Initiative has awarded a EUR 24 million
grant to the IMAGIO consortium of clinical partners coordinated by
Philips, with additional resources and funding from industry
partners
- The consortium will carry out research into improving clinical
outcomes through less invasive treatments for lung cancer, liver
cancer and soft tissue sarcomas
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced that the Philips-coordinated IMAGIO consortium [1] of
clinical partners has been awarded a EUR 24 million Innovative
Health Initiative (IHI) grant, complemented with additional
resources and funding from industry partners [2], to carry out
research into less invasive cancer treatments. Consisting of
approximately 30 partners, the consortium will use the funding to
improve clinical outcomes with interventional oncology innovations
focused on lung cancer, liver cancer and soft tissue sarcomas.
Leading European hospitals participating in the consortium include
Leiden, Maastricht, Radboud and Utrecht University Medical Centers
in the Netherlands and University Hospital of Cologne in
Germany.
In Europe about 2.7 million people are diagnosed with cancer
each year [3]. While significant advances have been made in
treatment, many approaches continue to have negative side effects,
impacting healthy tissues as well as targeting the cancer itself.
The aim of interventional oncology is the very precise treatment of
cancer cells with small instruments supported by imaging modalities
such as MRI, ultrasound and CT. Treatment is carried out through
targeted surgery, radiotherapy, chemotherapy, immunotherapy, or
high-intensity focused ultrasound. In addition to reducing damage
to healthy tissues, expanding the use of minimally or non-invasive
procedures also decreases the need for major surgery.
"By bringing together leading university medical centers,
academic partners, patient and healthcare professional
organizations, as well as smaller and larger companies in the
medical technology and pharmaceutical industry, the IMAGIO
consortium has the potential to make a significant impact on
improving cancer treatment,” said Bert van Meurs, Chief Business
Leader Image Guided Therapy and Chief Business Leader Precision
Diagnosis (ad interim) at Royal Philips. “We’ve chosen to focus on
liver and lung cancer – two leading causes of death – alongside
soft tissue sarcomas, a highly aggressive form of cancer that
affects a significant proportion of young individuals, causing a
lot of human suffering. By advancing established treatments and
developing new approaches, we aim to improve clinical
outcomes.”
Specific projects taking place in the consortium include:
- Collaboration with Radboud University Medical Center and other
partners including Jansen Pharmaceutica, Pfizer, Flash Pathology,
VU, ETH, ImaginAb Inc. and Eberhards Karls University Tübingen to
further expand diagnosis and minimally invasive treatment of lung
cancer supported by Philips' Azurion image-guided therapy
platform. Read more.
- Collaboration with Leiden and Maastricht University Medical
Centers to improve the diagnosis and treatment of liver cancer
using CT, ultrasound, precision marking and ablation
technology.
- Collaboration with University Medical Center Utrecht and TU
Delft to improve the treatment of liver cancer through
radioembolization (a type of radiation therapy) supported by hybrid
imaging modalities. Read more.
- Collaboration between University Hospital of Cologne, Profound
Medical and Philips to treat soft tissue sarcomas with MR-guided
high intensity focused ultrasound (MR-HIFU) in combination with
Thermosome’s lead drug candidate THE001, which is a thermosensitive
liposomal formulation of doxorubicin developed in soft tissue
sarcoma.
[1] The IMAGIO consortium – IMaging and Advanced Guidance for
workflow optimization in Interventional Oncology – includes the
following partners Philips, UMC Utrecht, LUMC, University Hospital
of Cologne, TU Delft, Radboudumc, Luxium Solutions, Flash
Pathology, Vrije Universiteit Amsterdam, Profound Medical,
Gremse-IT, Thermosome, MUMC+, Nederlandse Leverpatiënten
Vereniging, Fondazione IRCCS Istituto Nazionale Dei Tumori,
Eberhards Karls University Tübingen, European Cancer Patient
Coalition, Stichting Longkanker Nederland, ImaginAb Inc., Pfizer
Inc., Universiteit Twente, Nanovi, Turku University Hospital, SIOP
Europe, Janssen Pharmaceutica; and associated partners
Eidgenössische Technische Hochschule Zürich and The Newcastle Upon
Tyne Hospitals NHS Foundation Trust. [2] The industry partners are
members of COCIR, EFPIA, EuropaBio and MedTech Europe.[3] European
Commission, Europe's Beating Cancer Plan
https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf.
This project is supported by the Innovative Health Initiative
Joint Undertaking (JU) under grant agreement No 101112053. The JU
receives support from the European Union’s Horizon Europe research
and innovation program and life science industries represented by
COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe.
Disclaimer: IMAGIO is funded by the European Union, private
members, and those contributing partners of the IHI JU. Views and
opinions expressed are however those of the author(s) only and do
not necessarily reflect those of the aforementioned parties.
Neither of the aforementioned parties can be held responsible for
them.
For further information, please contact:Mark
GrovesPhilips Global Press Office Tel: +31 631 639
916 Email: mark.groves@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2022 sales of EUR 17.8 billion and employs approximately
74,000 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
- IMAGIO consortium logo (IMaging and Advanced Guidance for
workflow optimization in Interventional Oncology)
- IMAGIO partners meet for the kick-off
- Philips Azurion Image Guided Therapy Platform
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Apr 2023 a Apr 2024
